KODKodiak Sciences Inc.

Nasdaq kodiak.com


$ 2.77 $ -0.03 (-1.08 %)    

Thursday, 13-Jun-2024 15:59:58 EDT
QQQ $ 476.97 $ 2.57 (0.54 %)
DIA $ 386.89 $ -0.81 (-0.21 %)
SPY $ 542.45 $ 1.09 (0.2 %)
TLT $ 93.85 $ 1.36 (1.47 %)
GLD $ 212.97 $ -1.75 (-0.82 %)
$ 2.76
$ 2.78
$ 0.00 x 0
$ 0.00 x 0
$ 2.76 - $ 2.79
$ 1.37 - $ 9.67
128,237
na
144.93M
$ 1.56
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-15-2024 03-31-2024 10-Q
2 03-28-2024 12-31-2023 10-K
3 11-14-2023 09-30-2023 10-Q
4 08-14-2023 06-30-2023 10-Q
5 05-15-2023 03-31-2023 10-Q
6 03-28-2023 12-31-2022 10-K
7 11-09-2022 09-30-2022 10-Q
8 08-09-2022 06-30-2022 10-Q
9 05-10-2022 03-31-2022 10-Q
10 03-01-2022 12-31-2021 10-K
11 11-09-2021 09-30-2021 10-Q
12 08-09-2021 06-30-2021 10-Q
13 05-10-2021 03-31-2021 10-Q
14 03-01-2021 12-31-2020 10-K
15 11-09-2020 09-30-2020 10-Q
16 08-10-2020 06-30-2020 10-Q
17 05-11-2020 03-31-2020 10-Q
18 03-16-2020 12-31-2019 10-K
19 11-12-2019 09-30-2019 10-Q
20 08-14-2019 06-30-2019 10-Q
21 05-15-2019 03-31-2019 10-Q
22 03-27-2019 12-31-2018 10-K
23 11-16-2018 09-30-2018 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 kodiak-sciences-q1-2024-gaap-eps-082-beats-107-estimate

Kodiak Sciences (NASDAQ:KOD) reported quarterly losses of $(0.82) per share which beat the analyst consensus estimate of $(1.07...

 reported-earlier-kodiak-sciences-announced-treatment-of-first-patients-in-phase-3-glow2-study-of-tarcocimab-tedromer-in-diabetic-retinopathy

Kodiak Sciences Inc. (NASDAQ:KOD), a biopharmaceutical company committed to researching, developing and commercializing transfo...

 kodiak-sciences-data-at-arvo-2024-highlight-depth-of-early-and-late-phase-retina-pipeline-including-advancements-with-high-drug-antibody-ratio-therapeutics-built-on-kodiaks-antibody-biopolymer-conjugate-platform

Tarcocimab clinical and non-clinical data highlight strong 6-month efficacy profile in diabetic retinopathy patients and contin...

 ubs-maintains-neutral-on-kodiak-sciences-raises-price-target-to-5

UBS analyst Eliana Merle maintains Kodiak Sciences (NASDAQ:KOD) with a Neutral and raises the price target from $3 to $5.

 barclays-maintains-underweight-on-kodiak-sciences-raises-price-target-to-3

Barclays analyst Gena Wang maintains Kodiak Sciences (NASDAQ:KOD) with a Underweight and raises the price target from $2 to $3.

 why-kodiak-sciences-shares-are-trading-lower-by-around-20-here-are-other-stocks-moving-in-thursdays-mid-day-session

Shares of Kodiak Sciences Inc. (NASDAQ: KOD) fell sharply during Thursday’s session after the company reported a wider-than-e...

 us-stocks-flat-initial-jobless-claims-fall-to-210000

U.S. stocks traded mixed this morning, with the Dow Jones index trading almost flat on Thursday. Following the market opening ...

 kodiak-sciences-q4-eps-113-misses-077-estimate

Kodiak Sciences (NASDAQ:KOD) reported quarterly losses of $(1.13) per share which missed the analyst consensus estimate of $(0....

 earnings-scheduled-for-march-28-2024

Companies Reporting Before The Bell • Universal Stainless (NASDAQ:USAP) is expected to report quarterly earnings at $0.32 per ...

 ubs-maintains-neutral-on-kodiak-sciences-lowers-price-target-to-3

UBS analyst Eliana Merle maintains Kodiak Sciences (NASDAQ:KOD) with a Neutral and lowers the price target from $4 to $3.

 why-bluebird-bio-shares-are-trading-higher-here-are-other-stocks-moving-in-mondays-mid-day-session

Shares of bluebird bio, Inc. (NASDAQ: BLUE) rose sharply during Monday’s session after the company presented updated data from ...

 goldman-sachs-reinstates-sell-on-kodiak-sciences-announces-2-price-target

Goldman Sachs analyst Andrea Tan reinstates Kodiak Sciences (NASDAQ:KOD) with a Sell and announces $2 price target.

 capital-one-upgrades-kodiak-sciences-to-overweight

Capital One analyst Zegbeh Jallah upgrades Kodiak Sciences (NASDAQ:KOD) from Equal-Weight to Overweight.

 why-dolby-laboratories-shares-are-trading-lower-by-around-8-here-are-other-stocks-moving-in-fridays-mid-day-session

Shares of Dolby Laboratories, Inc. (NYSE: DLB) fell during Friday’s session following weak guidance.

 kodiak-sciences-q3-eps-095-beats-121-estimate

Kodiak Sciences (NASDAQ:KOD) reported quarterly losses of $(0.95) per share which beat the analyst consensus estimate of $(1.21...